News Column

CTLM(R) 3D Laser Breast Imaging System Sold and Shipped to Romania

Nov 5 2012 12:00AM

Marketwire

LogoTracker

FORT LAUDERDALE, FL -- (Marketwire) -- 11/05/12 -- Imaging Diagnostic Systems, Inc. (OTCBB: IMDS), a pioneer in laser breast imaging, announced today that it has shipped a CTLM® system to Euromedica Hospital in Baia Mare, Romania. This exciting event was possible through the joint efforts of the exclusive CTLM® distributor for Romania, Lebada USA, Inc. and the Romanian American Board of Trade.

Ovidius T. Lebada, CEO of the Lebada USA, Inc., states, "The recent shipment to Euromedica Hospital is just one of several CTLM® systems planned for the Romanian market. The CTLM®'s revolutionary technology offers 3D laser imaging of the breast with no harmful radiation, no compression, and no injected contrast agents. The CTLM® system is expected to be warmly received by the Romanian health care system. Women in Romania will soon have a new diagnostic tool to provide more information to aide in early detection of breast cancer. Through this and future installations, we look forward to assisting the imaging needs of women in Romania and hopefully other areas in Europe."

Euromedica Hospital, the first Romanian private Hospital accredited by CoNAS, the National Hospital Accreditation Committee, provides a wide range of care from outpatient medical consultations, laboratory tests, clinical investigations, hospitalization, surgery and post-surgery hospitalization. The hospital is equipped with the latest technical equipment for examinations and treatments. Its specialized medical personnel help ensure the highest quality of patient care. The non-invasive CTLM® will be a welcome addition to the diagnostic department at the hospital and will help keep them at the forefront of technology.

Linda Grable, CEO of IDSI, commented, "We are excited that the innovative and patented CTLM® system will be at Euromedica Hospital in Romania. The ground-breaking technology called diffused optical tomography (DOT) is the basis of the 3D breast imaging provided by CTLM®. The CTLM® is designed to help deliver additional diagnostic information, especially in some of the most difficult cases such as dense breasts. Future installations of CTLM® systems in Romania and across Europe are anticipated. Lebada USA, Inc. has received support from the Romanian American Board of Trade to help achieve this installation. IDSI is thrilled that Lebada USA, Inc. has worked so hard to make this happen. This is a major step toward assisting women's imaging needs in Romania."

Imaging Diagnostic Systems, Inc. is the developer of the CTLM® system; a revolutionary optical breast imaging device. Optical mammography is a diffuse optical tomography (DOT) technique that aims at detecting breast cancer. The CTLM® system utilizes patented continuous wave laser technology and computed algorithms to create 3D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. The CTLM system has received certification and licenses to sell internationally through the following approvals: European CE marking, Health Canada, China SFDA, UL, ISO 13485:2003, FDA export certification. Marketing clearances pending are Mexico COFEPRIS and Russian GOST-R.

For more information, visit our website: www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc. is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.



Contact:
Investor Relations
954-581-9800





Source: Marketwire


Story Tools